Regeneron ' s New Drug Price Could Disappoint Everyone. Here ' s Why That ' s A Good Thing

Regeneron ' s billionaire chief executive Leonard Schleifer has said that the drug industry ' s pricing is " ridiculous. " So when his own new drug, Dupixent for eczema, was approved, he took an unorthodox path to setting its $37,000-a-year list price.

Source: Forbes.com Healthcare News - March 28, 2017 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:REGN NYSE:CVS NASDAQ:ESRX NASDAQ:GILD Source Type: news